Navigation Links
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Date:10/25/2010

ducted primarily at the Fred Hutchinson Cancer Research Center in Seattle, WA and was supported, in large part, by a National Institutes of Health (NIH) grant.  The impetus for this NIH-funded prevention study came from two double-blind, randomized, placebo-controlled trials showing that orBec® was effective and safe as a treatment for acute gastrointestinal (GI) GVHD.  

Paul J. Martin, MD, Principal Investigator for the Phase 2 study and a Member, Fred Hutchinson Cancer Research Center stated, "Trials with orBec® have shown a consistent and positive clinical response in the treatment of acute GI GVHD.  We therefore designed a trial to determine whether orBec® could be used to prevent GVHD. Preliminary analysis indicates that administration of orBec®  starting before transplantation did not provide a statistically significant clinical advantage in preventing acute GVHD in this study, possibly because of confounding factors associated with the chemotherapy or radiation.  Preventive administration of orBec® to reduce the incidence or severity of GVHD warrants further investigation, for example, by starting orBec® dosing after transplantation, closer to the initial inflammatory insult of acute GVHD.  We are continuing to analyze the data in order to gain a better understanding of potential preventive treatment effects in this patient population and to determine the best approach for subsequent study."   

Dr. Martin continued, "In my mind, the results from this prevention study have no clinical implication regarding the likelihood of success in the ongoing Phase 3 study of orBec® for the treatment of acute GI GVHD."

"This Phase 2 clinical trial was truly proof-of-concept and the first of its kind. It was an aggressive approach to determining if a topically-a
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  IntelliQuit™, the world,s first smartphone breathalyzer for smokers, was selected to present as ... New York City on Wednesday April 22.  ... ... ... Thirty percent (30%) of all cardiovascular disease is caused ...
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... April 21, 2015  Navitas has launched Aviator, a ... range of offerings for life sciences clients. Aviator supports ... platform enabling seamless flow of data across all applications ... launch, Navitas worked closely with Oracle to provide Argus, ... CTMS in the Cloud. ...
Breaking Medicine Technology:IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 2Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 4
... June 21 Gentris Corporation ( www.gentris.com ), ... that Rick Williams has joined the organization ... Board of Directors.  In his role as CEO of ... continues to provide biotechnology and pharmaceutical sponsors with the ...
... 21 Thomson Reuters announced today that it has launched ... the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around ... , ... with drugs in development. It enables authorized users to share essential ...
Cached Medicine Technology:Gentris Corporation Names New Chief Executive Officer 2Gentris Corporation Names New Chief Executive Officer 3Gentris Corporation Names New Chief Executive Officer 4Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3
(Date:4/21/2015)... Chicago, IL (PRWEB) April 21, 2015 ... surgery provider in India for their ongoing commitment to ... Hyderabad strives to provide patients with the best ... to the skin, hair and body. , Executives at ... believes in the philosophy of — nothing about you, ...
(Date:4/21/2015)... Lewisville, TX (PRWEB) April 21, 2015 ... (NYSE:ADPT) announced today it is opening its first freestanding ... located in Chandler, Arizona and will be licensed under ... of the Dignity Health and Adeptus Health joint venture. ... Chandler Regional and Mercy Gilbert Medical Centers said the ...
(Date:4/21/2015)... Information is the best weapon in the fight ... patients and their families with knowledge about living with cancer ... is the Answer" and new website . , In ... patients from diagnosis through treatment and even death. The goal, ... treatment, at home and in the examination room. , “Cancer ...
(Date:4/21/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining ... SUVs. , SUVs are large vehicles that fare well ... and a smaller regular car shows that passengers from the ... SUV safer in crashes, but these large vehicles may be ... , It is now possible to find low cost car ...
(Date:4/21/2015)... QuickMedical, a veteran-owned leader in the ... Schiller America's line of Ambulatory and ... Vital Signs Monitors, among many other items. ... leader in the development and production of cardio-pulmonary ... cooperation with the world's leading physicians and specialists ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Auto Insurance Quotes For SUVs Are Available Online 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3
... world-leading publisher of scientific, technical, and medical information products ... January 2009, the internationally respected Journal of Pain ... be the official journal of the American Academy of ... will continue to serve as the official journal ...
... in Laser and Endoscopic Surgery , , ... Schaeffer, endoscopic reconstructive surgeon and leading nasal expert, has retained ... cosmetic practice. , , ... face, neck, sinuses and skull base, Dr. Schaeffer is credited ...
... 17 Cadence Pharmaceuticals, Inc.,(Nasdaq: CADX ... 304, a,Phase III clinical trial of Acetavance(TM), the ... acute pain following,abdominal laparoscopic surgery. Study 304 ... reduction in summed pain intensity,differences from baseline over ...
... NEW YORK, Dec. 17 Forest Laboratories, Inc. (NYSE: ... Chief Executive Officer exercised stock options for 600,000 shares which ... their 10-year term. Mr. Solomon indicated his intent to ... option exercise, net of those shares withheld by the Company ...
... is linked to hepatitis B, researchers say , , ... increased overall survival in Asian-Pacific patients with advanced liver ... included 226 patients in China, South Korea and Taiwan. ... 400 milligrams of sorafenib (Nexavar) twice a day in ...
... Internet,s fastest-growing job site, predicts the job sectors most likely to ... ... McLean, VA (PRWEB) December 17, 2008 -- Jobfox, the ... trends to watch in 2009. The list includes the job ...
Cached Medicine News:Health News:Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM 2Health News:Rubenstein Public Relations Retained To Provide Publicity for Foremost Nasal and Cosmetic Surgeon 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 3Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 4Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 5Health News:Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares 2Health News:Drug Helps Asians Battling Liver Cancer 2Health News:The Obama Effect: New Job Trends to Watch in 2009 2Health News:The Obama Effect: New Job Trends to Watch in 2009 3
... The Fundus 20mm is a ... Lens. The Fundus 20mm provides ... increased 20mm contact element. The ... the contact element sits under ...
... The Volk Area Centralis® is excellent ... neovascularization and changes from macular degeneration, ... proliferative diabetic retinopathy and other retinal ... laser treatment of these conditions providing ...
... delivers the widest field of view ... .5x image magnification provides simultaneous visualization of ... providing a greater margin of safety during ... the ideal lens for visualization and treatment ...
... it the "Super 90". Volk's SuperField® has ... diagnosis for today's discriminating practitioner. Its ideal ... make it perfect as the primary high ... SuperField has been specifically designed for increased ...
Medicine Products: